Selective COX-2 inhibitors may pose a greater risk of hyperkalaemia than nonselective NSAIDs

By  

Reactions Weekly, Vol. 1, Iss. 1325, 2010-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Selective COX-2 inhibitors vs NSAIDs discussed

By  

Inpharma, Vol. 1, Iss. 1341, 2002-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Temporal Relationship between Use of NSAIDs, Including Selective COX-2 Inhibitors, and Cardiovascular Risk

By Motsko Stephen P.  

Drug Safety, Vol. 29, Iss. 7, 2006-01 ,pp. : 621-632

Adis International

Access to resources Recommend Favorite

Value of Information in the Osteoarthritis Setting: Cost Effectiveness of COX-2 Selective Inhibitors, Traditional NSAIDs and Proton Pump Inhibitors

By Latimer Nicholas  

PharmacoEconomics, Vol. 29, Iss. 3, 2011-03 ,pp. : 225-237

Adis International

Access to resources Recommend Favorite

Use and costs of anti-secretory and cardiovascular co-medication in osteoarthritis patients treated with selective or non-selective NSAIDS

By Simoens Steven   Coster Sandra   Ruyck Bernard   Stutz Petra   Laekeman Gert  

Pharmacy World and Science, Vol. 28, Iss. 5, 2006-10 ,pp. : 309-317

Springer Publishing Company

Access to resources Recommend Favorite